Skip to main content
TipRanks
Go Ultimate75% OFF

Apyx Medical (BOV) Q3 2026 Earnings Report

1 Followers

DE:BOV Q3 2026 EPS Results

Actual EPS
-EUR 0.04
Consensus EPS
-EUR 0.08
Beat/Miss
Beat by +EUR 0.05
One Year Ago EPS
-EUR 0.04

DE:BOV Q3 2026 Revenue Results

Actual Revenue
EUR 12.56M
Expected Revenue
EUR 11.89M
Beat/Miss
Beat by +EUR 667.04K
YoY Revenue Growth
+8.95%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
DE:BOV Upcoming Earnings

Apyx Medical's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:BOV Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-6.19%|
Earnings Call Sentiment|Positive

The call was broadly positive. Revenue and Surgical Aesthetics growth remained strong, AYON adoption and Power Lipo expansion generated favorable customer feedback, profitability metrics improved, operating cash usage declined, and full-year revenue guidance was reaffirmed. The main negatives were the substantial OEM decline, a slight gross-margin contraction, higher operating expenses, and the lack of a timeline for international AYON registrations.

Company Guidance

Apyx Medical reaffirmed full-year 2026 revenue guidance in the range of $59 million to $60 million, compared with $52.8 million reported for the year ended December 31, 2025, including Surgical Aesthetics segment revenue in the range of $54 million to $55 million, compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5 million, compared with approximately $7.5 million for 2025; it now expects gross margins in the range of 63% to 64% and total operating expense targets in the range of $41 million to $42.5 million, versus previously stated operating expenses of less than $45 million, and stated that it will grow the Surgical Aesthetics business 20%. Management expects Q4 to be a very good handpiece quarter as well as a good capital quarter, and said Q4 is always its best capital quarter.

  • Total Revenue GrowthThird-quarter 2026 total revenue was $14 million, up 9% from $12.9 million in the prior-year period. Growth was driven primarily by AYON sales in the United States and Renuvion sales outside the United States, reflecting continued demand for the company's body contouring technologies.
  • Surgical Aesthetics Segment ExpansionSurgical Aesthetics revenue increased 17%, or $1.9 million, to $13 million in the third quarter, and grew 26% for the first nine months of 2026 compared with the same periods last year. Quarterly growth was driven by AYON sales and increased international generator sales.
  • AYON Power Liposuction LaunchThe company broadly rolled out AYON's power liposuction capability after receiving clearance and launching commercially. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing surgeon effort, and management estimates that approximately 70% of plastic surgeons use power liposuction. Surgeon feedback has been very positive, and activation requires a software update plus the purchase of a handpiece and cannula without system downtime.
  • AYON Adoption and Customer ExpansionManagement said AYON adoption has continued to build during the year since its full commercial launch. Approximately 75% of AYON sales have been to existing Renuvion customers and approximately 25% have been to customers new to Apyx. The company said more doctors are using the full AYON suite, including both power and ultrasonic liposuction.
  • Reported Clinical and Practice Benefits of AYONDoctors using AYON have reported less bruising and downtime for patients, faster recovery, integrated fat-transfer capabilities, greater procedural efficiency, and time savings for doctors and their teams. Management also said some doctors are using the technology to attract new patients, convert more patients to procedures, and in some cases charge more for procedures using the latest technology.
  • Renuvion Remains Central to the StrategyRenuvion continues to be positioned both as a standalone system and as an integrated component of AYON. Management said its tissue-contraction capability complements fat removal by helping address skin laxity after liposuction or significant weight loss.
  • New Renuvion Skin-Quality EvidenceA prospective study published in September enrolled 7 patients undergoing facelift surgery, with 6 completing the six-month follow-up. Treated tissue showed 30% greater elastin fiber density and 34% less inflammation than untreated control areas, and all 6 patients reported improved skin quality and satisfaction with their outcomes.
  • Additional Renuvion ApplicationsManagement cited studies showing that pretreating areas with Renuvion before fat transfer can produce up to 40% higher fat-graft retention. The company also said Renuvion's skin-quality and tissue-contraction applications may support additional use in body contouring.
  • Potential GLP-1-Related Body Contouring OpportunityManagement said continued adoption of GLP-1 medications is reshaping the body contouring patient population. The company believes patients achieving substantial weight loss may seek procedures addressing loose or lax skin and residual fat, and said the combination of advanced fat removal and Renuvion tissue contraction positions Apyx to address those needs.
  • Improved Profitability MetricsLoss from operations improved to $0.6 million from $0.8 million in the prior-year quarter. Net loss attributable to shareholders improved to $1.8 million, or $0.04 per share, from $2 million, or $0.05 per share. Adjusted EBITDA improved to positive $0.4 million from a loss of $0.1 million, and the company reported positive EBITDA on a cumulative trailing 12-month basis.
  • Operating Cash Flow and LiquidityNet cash used in operating activities declined to $1.6 million from $3.5 million in the prior-year period, primarily due to working-capital changes and a lower net loss. The company had $25.8 million of cash and cash equivalents at September 30, 2026, and reported average cash burn of approximately $2 million per quarter for the year.
  • Full-Year Revenue Guidance ReaffirmedThe company reaffirmed 2026 revenue guidance of $59 million to $60 million, compared with $52.8 million reported for 2025. Surgical Aesthetics guidance remains $54 million to $55 million versus approximately $45.3 million in 2025, while OEM revenue is expected to be approximately $5 million versus approximately $7.5 million in 2025.
  • Lower Operating Expense TargetThe company updated its full-year 2026 operating expense target to $41 million to $42.5 million, compared with its previous target of less than $45 million. Management attributed the improved profitability to growing the top line while managing the bottom line and said it remains focused on reaching profitability as quickly as possible.
  • International AYON and Reconstructive OpportunitiesApyx is working on registrations for AYON in Europe, the Middle East, and key Latin American countries including Brazil, Colombia, and Mexico. Management said hospital-based procedures and teams of doctors in Europe could increase the value of AYON's simultaneous activation capabilities, which can perform up to four activities at the same time. The company also identified reconstructive procedures and hospitals as an opportunity in international markets and in the United States.
  • Expected Fourth-Quarter Procedure-Related DemandManagement expects the fourth quarter to be a good handpiece quarter because the greatest number of procedures are performed in the fourth quarter rather than the third quarter. It also expects the fourth quarter to be a good capital quarter and described it as historically its best capital quarter.

DE:BOV Earnings History

DE:BOV earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)-0.03--0.03――
Nov 05, 20262026 (Q3)-0.08-0.04-0.0420.00% (+0.01)
Aug 06, 20262026 (Q2)-0.07-0.06-0.0822.22% (+0.02)
May 07, 20262026 (Q1)-0.10-0.04-0.0950.00% (+0.04)
Mar 10, 20262025 (Q4)-0.05-0.03-0.1175.00% (+0.08)
Nov 06, 20252025 (Q3)-0.09-0.04-0.1364.29% (+0.08)
Aug 07, 20252025 (Q2)-0.08-0.08-0.1752.63% (+0.09)
May 08, 20252025 (Q1)-0.11-0.09-0.254.55% (+0.11)
Mar 13, 20252024 (Q4)-0.14-0.11-0.2557.14% (+0.14)
Nov 08, 20242024 (Q3)-0.16-0.13-0.12-7.69% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed